July 8, 2009 - High-Intensity-Focused Ultrasound (HIFU), which uses high-frequency sound waves to heat up tissue, is an experimental cancer therapy for prostate cancer that may be able to treat men without surgery and offer fewer side effects, according to the results of a study published in the British Journal of Cancer.

In the study, which took place at University College Hospital in London and the privately owned Princess Grace Hospital in London, treated a group of 172 men with prostate cancer that had not spread were treated under general anaesthetic with HIFU.

The men taking part in the trial were discharged on average five hours after receiving the HIFU treatment. Typically men with prostate cancer are treated with either surgery or radiotherapy. Surgery usually requires a two to three day inpatient stay and radiotherapy requires daily treatment as an outpatient for up to one month.

Of the initial group, 159 men were followed up a year later and 92 percent did not have any recurrence of prostate cancer. Although this was not a comparative study, it would be expected that traditional treatments for early prostate cancer of surgery or radiotherapy would show a similar percentage of men showing no recurrence of their prostate cancer one year on.

Less than one percent - one man of the 159 followed up - had incontinence. And 30-40 percent had impotence. None had any bowel problems.

Ahmed et al. High-Intensity-Focused Ultrasound in the treatment of primary prostate cancer: the first UK series. 1 July, 2009. British Journal of Cancer.

For more information: www.ukhifu.co.uk


Related Content

News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Women's Health

March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...

Time March 03, 2026
arrow
News | FDA

Feb. 26, 2026 — AS Software, a provider of specialty-focused ultrasound reporting solutions, has announced that the U.S ...

Time March 02, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
Subscribe Now